High-Frequency Jet Ventilation Seems Safe for Lung Ablation
29 Jan 2024
Radiation TherapyClinical Result
MONDAY, Jan. 29, 2024 -- For percutaneous lung ablation, high-frequency jet ventilation (HFJV) under general anesthesia seems as safe as spontaneous respiration (SR) under moderate sedation, with longer room time for HFJV, according to a study published online Jan. 24 in the American Journal of Roentgenology.
Alexander Graur, from Massachusetts General Hospital in Boston, and colleagues conducted a retrospective study involving consecutive adults who underwent computed tomography (CT)-guided percutaneous cryoablation of one or more lung tumors with HFJV or SR. Major adverse events within 30 days and hospital length of stay (HLOS) at least two days were compared among 139 patients with 310 lung tumors who underwent 208 cryoablations (129 HFJV and 79 SR).
The researchers found that the rates were greater for HFJV versus SR for treatment of multiple tumors per session (43 versus 19 percent) and nonperipheral tumor location (48 versus 24 percent). The major adverse event rate did not differ significantly between the groups (8 versus 5 percent). There were no occurrences of systemic air embolism. HLOS of at least two days occurred in 17 percent of sessions, with no significant difference noted for HFJV versus SR. No significant difference was seen in procedure time, CT guidance acquisition time, CT guidance radiation dose, or total radiation dose between ventilation modalities. Longer room time was seen for HFJV versus SR (154 versus 127 minutes).
"The choice of ventilation modality in percutaneous lung ablation should be based on patient characteristics and anticipated procedural requirements, as well as operator preference," the authors write.
One author disclosed ties to Pfizer and Boston Scientific.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.